SCHEMBL3209201

SCHEMBL3209201

Cc1ccc(N2CCN(S(=O)(=O)c3ccc4ccccc4c3)CC2)c(C)c1

nearest known ligand 0.69

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
HTT P42858 5/20 0.68
MAPK1 P28482 2/20 0.68
MAPT P10636 2/20 0.68
LMNA P02545 7/20 0.67
SMN1; SMN2 Q16637 5/20 0.67
GAA P10253 1/20 0.67
PKM P14618 3/20 0.67
POLB P06746 2/20 0.64
MCOLN3 Q8TDD5 3/20 0.57
TSHR P16473 2/20 0.57
USP2 O75604 1/20 0.56
L3MBTL1 Q9Y468 1/20 0.56
MEN1 O00255 1/20 0.55
KMT2A Q03164 1/20 0.55
ALDH1A1 P00352 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23051855 0.88 SMN1; SMN2 (0.71) HTTMAPK1MAPTLMNASMN1; SMN2
SCHEMBL18134604 0.81 MCOLN3 (0.83) HTTLMNASMN1; SMN2PKMMCOLN3
SCHEMBL3213203 0.81 TDP1 (0.70) HTTMAPK1MAPTLMNASMN1; SMN2
SCHEMBL2839143 0.81 LMNA (0.76) HTTMAPK1MAPTLMNASMN1; SMN2
SCHEMBL2950531 0.81 LMNA (0.71) HTTMAPK1MAPTLMNASMN1; SMN2
SCHEMBL3213621 0.80 PKM (0.71) HTTMAPTLMNASMN1; SMN2PKM
SCHEMBL20772166 0.79 HSD11B1 (0.73) HTTMAPK1MAPTLMNASMN1; SMN2
SCHEMBL3212035 0.78 CTDSP1 (0.62) HTTLMNASMN1; SMN2PKMMCOLN3
SCHEMBL3219662 0.78 PKM (0.63) HTTMAPK1MAPTLMNASMN1; SMN2
SCHEMBL2961007 0.78 SMN1; SMN2 (0.80) HTTMAPK1MAPTLMNASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100029648-A1 11-Beta HSD1 Inhibitors XIANG JASON SHAOYUN 2010-02-04 US disclosed
US-7632838-B2 11-beta HSD1 inhibitors WYETH (US) 2009-12-15 US disclosed
EP-1981848-A2 11-BETA HSD1 INHIBITORS Wyeth (US) 2008-10-22 EP disclosed
US-20070219198-A1 11-Beta HSD 1 inhibitors WYETH (US) 2007-09-20 US disclosed
WO-2007092435-A2 11-BETA HSD1 INHIBITORS WYETH (US) 2007-08-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100029648-A1 11-Beta HSD1 Inhibitors HSD11B1, HSD3B1, HSD11B2 HTT 1959/4885MAPK1 837/4885MAPT 3352/4885
US-20070219198-A1 11-Beta HSD 1 inhibitors HSD11B1, HSD11B2, HSD3B1 HTT 1640/4885MAPK1 651/4885MAPT 3097/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.